<DOC>
	<DOCNO>NCT00252161</DOCNO>
	<brief_summary>The aim study evaluate survival benefit TS-1 plus cisplatin neoadjuvant chemotherapy gastric cancer patient resectable type 4 ( linitis plastica type ) large type 3 tumor comparison surgery alone .</brief_summary>
	<brief_title>A Trial Neoadjuvant TS-1 Cisplatin Type 4 Large Type 3 Gastric Cancer</brief_title>
	<detailed_description>A randomized phase III study go start Japan compare TS-1 plus cisplatin neoadjuvant chemotherapy surgery alone patient type 4 large type 3 gastric cancer.A total 300 patient accrue study 35 institution within five year . The primary endpoint overall survival . The secondary endpoint progression free survival ( PFS ) , response rate , proportion protocol achievement , proportion curative resection , adverse event .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1. histologically proven adenocarcinoma stomach 2 . Borrmann type 4 large ( &gt; =8 cm ) type 3 3. evidence distant metastasis include liver ( M0 ) 4. evidence paraaortic and/or retropancreatic lymph node metastasis ( N02 ) 5. peritoneal metastasis negative peritoneal lavage cytology ( PLS ) laparoscopic confirmation 6. involvement esophagus &gt; 3cm 7. age 2075 year 8. Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 9. prior chemotherapy , radiotherapy malignancy 10. prior surgery gastric cancer except endoscopic membrane resection ( EMR ) 11. breed primary tumor gastrointestinal stenosis 12. sufficient oral intake 13. adequate organ function 14. write informed consent 1. synchronous metachronous ( within 5 year ) malignancy carcinoma situ 2. pregnant breastfeed woman 3. severe mental disease 4. systemic administration corticosteroid , flucytosine , phenytoin warfarin 5. severe complication paralytic ileus , intestinal pneumonitis , pulmonary fibrosis , ischemic heart disease 6. myocardial infarction within six diseasefree month</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Neoadjuvant Therapy</keyword>
	<keyword>Stomach Neoplasms</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>S-1 ( combination )</keyword>
</DOC>